Bausch + Lomb Phase 2 Pain Study Misses Primary Goal

BL1332 showed numerically greater pain relief than vehicle but did not reach statistical significance on the primary endpoint.

Updated on Nov. 19, 2026 in Healthcare

Bold vector editorial illustration of an unlabeled amber eye-dropper bottle with a single blue droplet above its tip, centered in generous negative space.
Bausch + Lomb's Phase 2 study of BL1332 for post-surgical ocular pain missed its primary statistical-significance endpoint against vehicle, announced November 18, 2026. AI Illustration. Upload story photo >

Bausch + Lomb reported topline results from a Phase 2 study of BL1332 in post-surgical ocular pain, announced November 18, 2026. The study did not meet its primary endpoint of statistically significant improvement versus vehicle in summed pain intensity difference (SPID) over 24 hours.

Why it matters

The company is evaluating study designs, endpoints and patient populations that best align with the clinical profile observed in this study. The findings give a clearer picture of how BL1332 performs in post-surgical patients as the company determines its next steps for development.

Across 129 adults undergoing unilateral sequential PRK surgery for myopia, the 0.30% dose produced a -11.5 SPID difference versus vehicle and the 0.15% dose produced -9.0, with complete pain relief at six hours reported by 14.0% and 14.6% of patients versus 3.7% on vehicle. Whether these numerically greater reductions will be confirmed in a larger or differently designed study remains unresolved.

The players

Bausch + Lomb

Bausch + Lomb is a global eye health company headquartered in Vaughan, Ontario, that develops and markets eye care products and pharmaceuticals.

U.S. Food and Drug Administration (FDA)

The FDA is the U.S. federal agency responsible for regulating drugs, biologics and medical devices, including review of new ophthalmic treatments.

The details

Participants were randomized 2:2:1 to BL1332 0.30%, BL1332 0.15%, or vehicle, with treatment beginning immediately after surgery and five doses administered over 24 hours while awake for three days. Both BL1332 dose groups showed numerically greater pain relief than vehicle across every SPID analysis, and the 0.30% dose showed a nominally significant reduction in pain during the first six hours after surgery.

Timeline

  1. November 18, 2026: Bausch + Lomb announced Phase 2 topline results for BL1332.

  2. Follow-up in the study ran through Day 14 after surgery.

Healthcare Landscape

The result comes as sponsors of ophthalmic pain treatments weigh how to design post-surgical trials around SPID endpoints, a measure the FDA has relied on in prior ocular pain reviews. Bausch + Lomb's decision on endpoints and patient populations will test whether a numerically consistent but non-significant signal can support the next trial.

For patients undergoing PRK, BL1332 remains investigational and is not yet available, so current post-surgical pain management will continue unchanged. Any future product would depend on a successful regulatory path, which the trial's missed primary endpoint now makes more uncertain.

The takeaway

A trial can show consistent pain relief in its numbers and still fall short of statistical significance on its primary endpoint, which is why sponsors often redesign the next study before moving forward. Readers tracking eye-care drug development should watch for the company's next regulatory update.

Further reading

For related coverage, explore more Healthcare news on the business industry section.